We are live on ! Find out more
JP

John Paulson Paulson & Co

AUM $2.58B
1-Year Est. Return 68.51%
 

John Paulson is the founder of Paulson & Co., a firm that became world-famous for profits related to the 2007–2008 housing and credit crisis. Beyond that landmark trade, the firm has pursued merger arbitrage, event-driven, and opportunistic credit and equity strategies. Paulson remains one of the most recognized names in modern hedge fund history.

This Fund
S&P 500
This Quarter Est. Return
+6.03%
1 Year Est. Return
+68.51%
3 Year Est. Return
+251.48%
5 Year Est. Return
+229.81%
10 Year Est. Return
+881.28%
AUM
$7.4B
AUM Growth
-$138M
Cap. Flow
-$394M
Cap. Flow %
-5.32%
Top 10 Hldgs %
57.17%
Holding
127
New
29
Increased
18
Reduced
38
Closed
18

Top Buys

Rank Stock Value
1
VST icon
Vistra
VST
+$182M
2
AABA
Altaba Inc
AABA
+$146M
3
TMUS icon
T-Mobile US
TMUS
+$124M
4
VWR
VWR Corporation
VWR
+$83.7M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$61.4M

Top Sells

Rank Stock Value
1
STAY
Extended Stay America, Inc. Paired Share Unit
STAY
+$328M
2
AKRX
Akorn Inc
AKRX
+$202M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$132M
4
MJN
Mead Johnson Nutrition Company
MJN
+$105M
5
SHPG
Shire pic
SHPG
+$90.3M

Sector Composition

Rank Sector Weight
1 Healthcare 45.28%
2 Communication Services 14.29%
3 Consumer Discretionary 8.53%
4 Materials 5.2%
5 Technology 4.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDIT icon
101
Editas Medicine
EDIT
$478M
$839K 0.01%
50,000
– –
NTLA icon
102
Intellia Therapeutics
NTLA
$1.8B
$778K 0.01%
48,600
-30,000
-38% -$419K
SIEN
103
DELISTED
Sientra, Inc.
SIEN
$776K 0.01%
+7,980
New +$652K
CRSP icon
104
CRISPR Therapeutics
CRSP
$5.75B
$457K 0.01%
28,500
-22,000
-44% -$363K
TNDM icon
105
Tandem Diabetes Care
TNDM
$1.55B
$400K 0.01%
50,000
– –
HUN icon
106
Huntsman Corp
HUN
$1.75B
$336K ﹤0.01%
+13,000
New +$322K
ARDM
107
DELISTED
Aradigm Corp Common Stock
ARDM
$252K ﹤0.01%
192,727
– –
OKTA icon
108
Okta
OKTA
$23.5B
$171K ﹤0.01%
+7,500
New +$185K
ARCC icon
109
Ares Capital
ARCC
$14.3B
– –
-1
Closed –
BCRX icon
110
CALL
BioCryst Pharmaceuticals
BCRX
$2.44B
– –
-350,000
Closed -$2.94M
BIIB icon
111
Biogen
BIIB
$32B
– –
-17,300
Closed -$4.73M
EBAY icon
112
eBay
EBAY
$46.3B
– –
-471,200
Closed -$15.8M
ETSY icon
113
Etsy
ETSY
$7.44B
– –
-833,000
Closed -$8.86M
INSM icon
114
Insmed
INSM
$27.5B
– –
-90,000
Closed -$1.58M
PFE icon
115
Pfizer
PFE
$160B
– –
-429,505
Closed -$13.9M
SRPT icon
116
Sarepta Therapeutics
SRPT
$1.98B
– –
-78,101
Closed -$2.31M
OSG
117
DELISTED
Overseas Shipholding Group Inc.
OSG
– –
-45,139
Closed -$174K
CNCE
118
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-70,229
Closed -$1.2M
AKRX
119
DELISTED
Akorn Inc
AKRX
– –
-8,397,100
Closed -$202M
ALDR
120
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-74,000
Closed -$1.54M
NVDQ
121
PUT
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-500,000
Closed -$3.9M
NSR
122
DELISTED
Neustar Inc
NSR
– –
-200,000
Closed -$6.63M
MJN
123
DELISTED
Mead Johnson Nutrition Company
MJN
– –
-1,184,200
Closed -$105M
HW
124
DELISTED
Headwaters Inc
HW
– –
-100,000
Closed -$2.35M
WWAV
125
DELISTED
The WhiteWave Foods Company
WWAV
– –
-670,000
Closed -$37.6M
2 3 4
5
6

Similar funds

TC
Trilogy Capital Irvine, California $2.58B AUM 22.97% 1-Year Est. Return
RFP
Root Financial Partners Encinitas, California $2.57B AUM 21.7% 1-Year Est. Return
EV
Eclipse Ventures Palo Alto, California $2.57B AUM
MC
Moors & Cabot Boston, Massachusetts $2.57B AUM 37.84% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CTA
Chesley Taft & Associates Chicago, Illinois $2.57B AUM 22.93% 1-Year Est. Return
VWM
Venturi Wealth Management Austin, Texas $2.58B AUM 41.25% 1-Year Est. Return

John Paulson's Q2 2017 Portfolio in Review

As of Q2 2017, John Paulson held 127 positions worth $7.4B, down 1.8% from $7.53B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

John Paulson withdrew a net $394M in Q2 2017, closing 18 positions and reducing 38 holdings. Its most notable exit was Akorn Inc, an estimated $202M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

Against the trend, John Paulson opened a new position in Vistra worth $194M.

  • John Paulson's largest Q2 2017 buy was Vistra: 11,530,556 shares worth $194M.
  • John Paulson added most to T-Mobile US in Q2 2017, an estimated $124M increase.
  • John Paulson's biggest Q2 2017 reduction was Extended Stay America, Inc. Paired Share Unit, cutting an estimated $328M.
  • John Paulson fully exited Akorn Inc in Q2 2017, selling an estimated $202M.
  • John Paulson's ten largest holdings make up 57% of its $7.4B portfolio in Q2 2017.
  • John Paulson opened 29 new positions and closed 18 in Q2 2017.
  • John Paulson's portfolio value fell 1.8% quarter-over-quarter to $7.4B.

Based on Paulson & Co's 13F filing for Q2 2017, filed 14 Aug 2017.